Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel Area Business & Innovation. Germo Gericke from Novartis was named Chief Medical Officer. He also leads the activities in the Basel Area.
Germo Gericke leads the new subsidiary of Ariceum Therapeutics in Basel (img: Ariceum Therapeutics)
Ariceum Therapeutics has established a subsidiary in Basel. The private biotech company develops radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers. According to a press release, Germo Gericke from Novartis was named Chief Medical Officer.
Ariceum’s CEO Manfred Rüdiger comments, that the aim of opening the new subsidiary in Basel is to expand the team “to build a global development hub for Ariceum”. He adds that Germo Gericke is bringing a wealth of experience in the area of radiopharmaceutical therapy and that he will lead and develop the team for clinical development and operational processes from the new subsidiary in Basel.
Basel attracts talent from all over Europe
The new Chief Medical Officer Germo Gericke is convinced: “Basel is at the heart of the European Life Sciences industry. It offers a well-connected, business-friendly environment and great networking opportunities thanks to the cluster of sector activity in the area.” He added that the city’s central location attracts talent from all over Europe and beyond. “We offer exciting career development opportunities within a modern office space and the scope to benefit from the great living and working environment that Basel provides, and look forward to tapping into Basel Area’s talent pool.”
Gericke is coming from Advanced Accelerator Applications (AAA), a Novartis company that develops radioligand therapies and imaging radioligands for oncology indications. He was Chief Medical Officer and Head of Research and Development. According to a press release, Gericke has built a global R&D organization for radioligand therapies.
Ariceum Therapeutics with headquarters in Berlin was supported in its settlement in Switzerland by Basel Area Business & Innovation.